Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Gilead Sciences, Inc.

NASDAQ: GILD · Life Sciences · 12 alerts · CIK 882095

Share price
$167.58Close, Nov 16
Market cap
$208B
Shares outstanding
1.24BLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Gilead Sciences, Inc. filings on SEC EDGAR ↗

3:44 PM ET Form 4
Insider Selling

Gilead Sciences Insider Kelly A. Kramer Sells $1.76M of Stock

Kelly A. Kramer sold 10,376 shares of Gilead Sciences, Inc. at $168.23 to $171.44 a share (average $169.76) in 4 transactions, worth $1.76M in total on Nov 12, 2026. Shares held after the trade: 1,339 (-13.0%).

Value
$1.76M
Shares
10,376
Average price
$169.76
Holding change
-13.0%
Trade date
Nov 12, 2026
7:20 PM ET Form 4
Insider Selling

Gilead Sciences EVP Gen Counsel, Legal & Comp Wettan Keeley M. Cain Sells $558K of Stock

Wettan Keeley M. Cain, EVP Gen Counsel, Legal & Comp, sold 3,399 shares of Gilead Sciences, Inc. at $164.11 a share, worth $558K in total on Nov 6, 2026. Shares held after the trade: 5,360 (-38.8%).

Value
$558K
Shares
3,399
Price
$164.11
Role
EVP Gen Counsel, Legal & Comp
Holding change
-38.8%
Trade date
Nov 6, 2026
5:16 PM ET Form 4
Insider Selling

Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $19.7M of Stock

Daniel Patrick O'Day, Chairman & CEO, sold 112,429 shares of Gilead Sciences, Inc. at $175.16 to $175.17 a share (average $175.16) in 2 transactions, worth $19.7M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 551,683 (-1.7%).

Value
$19.7M
Shares
112,429
Average price
$175.16
Role
Chairman & CEO
Holding change
-1.7%
Trade date
Nov 4, 2026 to Nov 5, 2026
7:15 PM ET Form 4
Insider Selling

Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $5.33M of Stock

Daniel Patrick O'Day, Chairman & CEO, sold 30,881 shares of Gilead Sciences, Inc. at $167.40 to $175.25 a share (average $172.57) in 6 transactions, worth $5.33M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 551,683 (-0.4%).

Value
$5.33M
Shares
30,881
Average price
$172.57
Role
Chairman & CEO
Holding change
-0.4%
Trade date
Oct 30, 2026 to Nov 2, 2026
4:17 PM ET Form 4
Insider Selling

Gilead Sciences CFO Andrew D. Dickinson Sells $469K of Stock

Andrew D. Dickinson, CFO, sold 3,000 shares of Gilead Sciences, Inc. at $156.22 a share, worth $469K in total on Oct 15, 2026. Shares held after the trade: 161,096 (-1.8%).

Value
$469K
Shares
3,000
Price
$156.22
Role
CFO
Holding change
-1.8%
Trade date
Oct 15, 2026
4:12 PM ET Form 4
Insider Selling

Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier Sells $469K of Stock

Johanna Mercier, Chief Comm & Corp Aff Officer, sold 3,000 shares of Gilead Sciences, Inc. at $156.22 a share, worth $469K in total on Oct 15, 2026. Shares held after the trade: 113,684 (-2.6%).

Value
$469K
Shares
3,000
Price
$156.22
Role
Chief Comm & Corp Aff Officer
Holding change
-2.6%
Trade date
Oct 15, 2026
4:40 PM ET Form 4
Insider Selling

Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $2.22M of Stock

Daniel Patrick O'Day, Chairman & CEO, sold 15,000 shares of Gilead Sciences, Inc. at $147.72 to $148.63 a share (average $147.90) in 2 transactions, worth $2.22M in total on Oct 1, 2026. Shares held after the trade: 566,683 (-0.5%).

Value
$2.22M
Shares
15,000
Average price
$147.90
Role
Chairman & CEO
Holding change
-0.5%
Trade date
Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.